Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

TNFalpha mediates the skeletal effects of thyroid-stimulating hormone.

Hase H, Ando T, Eldeiry L, Brebene A, Peng Y, Liu L, Amano H, Davies TF, Sun L, Zaidi M, Abe E.

Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12849-54. Epub 2006 Aug 14.

2.

TSH is a negative regulator of skeletal remodeling.

Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M.

Cell. 2003 Oct 17;115(2):151-62.

3.

The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis.

Ma R, Morshed S, Latif R, Zaidi M, Davies TF.

Thyroid. 2011 Aug;21(8):897-906. doi: 10.1089/thy.2010.0457. Epub 2011 Jul 11.

4.

Genetic confirmation for a central role for TNF╬▒ in the direct action of thyroid stimulating hormone on the skeleton.

Sun L, Zhu LL, Lu P, Yuen T, Li J, Ma R, Baliram R, Moonga SS, Liu P, Zallone A, New MI, Davies TF, Zaidi M.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9891-6. doi: 10.1073/pnas.1308336110. Epub 2013 May 28. Erratum in: Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12498. Baliram, Ramkumari [corrected to Baliram, Ramkumarie].

5.

High-mobility group box proteins modulate tumor necrosis factor-alpha expression in osteoclastogenesis via a novel deoxyribonucleic acid sequence.

Yamoah K, Brebene A, Baliram R, Inagaki K, Dolios G, Arabi A, Majeed R, Amano H, Wang R, Yanagisawa R, Abe E.

Mol Endocrinol. 2008 May;22(5):1141-53. doi: 10.1210/me.2007-0460. Epub 2008 Jan 24.

6.
8.

Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.

Quinn JM, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N, Mizuno A, Higashio K, Takahashi N, Suda T, Martin TJ, Gillespie MT.

J Bone Miner Res. 2001 Oct;16(10):1787-94.

9.

Regulation of human osteoclast differentiation by thioredoxin binding protein-2 and redox-sensitive signaling.

Aitken CJ, Hodge JM, Nishinaka Y, Vaughan T, Yodoi J, Day CJ, Morrison NA, Nicholson GC.

J Bone Miner Res. 2004 Dec;19(12):2057-64. Epub 2004 Sep 20.

10.

Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.

Hayashi S, Yamada T, Tsuneto M, Yamane T, Takahashi M, Shultz LD, Yamazaki H.

J Immunol. 2003 Nov 15;171(10):5130-9.

11.

A RANKL-inducible gene Znf216 in osteoclast differentiation.

Hishiya A, Ikeda K, Watanabe K.

J Recept Signal Transduct Res. 2005;25(3):199-216.

PMID:
16194934
12.
14.

Identification and characterization of the precursors committed to osteoclasts induced by TNF-related activation-induced cytokine/receptor activator of NF-kappa B ligand.

Mochizuki A, Takami M, Kawawa T, Suzumoto R, Sasaki T, Shiba A, Tsukasaki H, Zhao B, Yasuhara R, Suzawa T, Miyamoto Y, Choi Y, Kamijo R.

J Immunol. 2006 Oct 1;177(7):4360-8.

16.

Fos plays an essential role in the upregulation of RANK expression in osteoclast precursors within the bone microenvironment.

Arai A, Mizoguchi T, Harada S, Kobayashi Y, Nakamichi Y, Yasuda H, Penninger JM, Yamada K, Udagawa N, Takahashi N.

J Cell Sci. 2012 Jun 15;125(Pt 12):2910-7. doi: 10.1242/jcs.099986. Epub 2012 Mar 27.

17.

Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.

Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y.

J Immunol. 2000 Oct 15;165(8):4254-63.

18.

Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation.

Zhang W, Zhang Y, Liu Y, Wang J, Gao L, Yu C, Yan H, Zhao J, Xu J.

J Biomech. 2014 Apr 11;47(6):1307-14. doi: 10.1016/j.jbiomech.2014.02.015. Epub 2014 Feb 19.

PMID:
24629929
19.
20.

Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.

Kanatani M, Sugimoto T, Sowa H, Kobayashi T, Kanzawa M, Chihara K.

J Cell Physiol. 2004 Oct;201(1):17-25.

PMID:
15281085

Supplemental Content

Support Center